5. Progressive supranuclear palsy
82 clinical trials,   107 drugs   (DrugBank: 36 drugs),   60 drug target genes,   90 drug target pathways

Searched query = "Progressive supranuclear palsy", "PSP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-007520-26-DE
(EUCTR)
24/06/201013/11/2009A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III)A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III) Progressive Supranuclear Palsy
MedDRA version: 12.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy
Trade Name: Azilect
INN or Proposed INN: Rasagilin
Other descriptive name: RASAGILINE MESILATE
Klinikum der Universität MünchenNULLNot RecruitingFemale: yes
Male: yes
Phase 3Germany